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The haematolymphoproliferative disorders (HLPD) are a hetero-
geneous group of neoplasms accounting for some 8.6% of all
tumours in males and 7.1% of all tumours in females reported to
the Swedish Cancer Registry in 1996 (Centre for Epidemiology,
1999). Non-Hodgkin’s lymphoma (NHL) is the most common
subgroup and its age-standardized incidence has increased annu-
ally by 2.5% on average since 1977, while the corresponding rates
of Hodgkin’s disease (HD), multiple myeloma (‘myeloma’) and
leukaemia have been relatively stable in Sweden. The rapid increase
in NHL incidence and mortality is a worldwide trend (Groves et al,
2000). Risk factors for HLPD are generally poorly understood
(Adami et al, 1995; Groves et al, 2000). Immunodeficiency states,
both genetic and those induced by medications or illness, are
associated with a markedly elevated risk of NHL (Kinlen, 1992;
Adami et al, 1995; Groves et al, 2000). There is evidence that
viruses, particularly the Epstein–Barr virus (EBV), may play a
role in the aetiology of NHL and HD (IARC, 1996, 1997).
Chemotherapeutic agents, pesticides and organic solvents are
associated with NHL risk, while ionizing radiation is associated
with myeloma and leukaemia (Groves et al, 2000). Recently,
suggestive evidence has been reported that exposure to ultraviolet
radiation (UVR) may increase the risk for NHL by causing
immune impairment (Cartwright et al, 1994; Adami et al, 1995;
Groves et al, 2000; IARC, 2001). A family history of HLPD is a
risk factor in a small proportion of HLPDs (Horwitz, 1997;
Hemminki et al, 1998; Yuille et al, 1998; Capalbo et al, 2000;
Shugart et al, 2000; Wiernik et al, 2000). 
The aetiology of second primary cancers is likely to be multi-
factorial and may include any of the above factors and interactions
among these (Greene and Wilson, 1985; Storm and Prener, 1985;
Travis et al, 1991; Adami et al, 1995; Sankila et al, 1995; Vaittinen
and Hemminki, 2000; Dong and Hemminki, 2001a). Shared risk
factors may cause certain malignancies to cluster more frequently
than expected. The study of multiple primary malignancies
following HLPD therefore has aetiological and clinical impor-
tance. In this nationwide study, we used the Swedish Family-
Cancer Database to systematically analyse the site-specific risk of
second primary neoplasm among 53 159 patients diagnosed with a
HLPD during 1958–1996 in Sweden (Vaittinen and Hemminki,
2000; Dong and Hemminki, 2001a). 
SUBJECTS AND METHODS 
The Swedish Family-Cancer Database 
The Swedish Family-Cancer Database, updated in 1999, was
formed from the Second Generation Register maintained by
Statistics Sweden and linked by the individually unique national
registration number to the Swedish Cancer Register at the National
Board of Health and Welfare. The Database includes all persons
born in Sweden after 1934 with their biological parents, totalling
over 9.6 million individuals (Hemminki and Vaittinen, 1999;
Hemminki and Dong, 2000a). Since 1958, all new cases of tumour
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BJOC 01-1998 997-1005  1/10/01  11:51 am  Page 997in Sweden have been reported to the Swedish Cancer Registry. An
almost 100% coverage has been achieved by compulsory reporting
by clinicians who diagnose a neoplasm, while pathologists and
cytologists must report separately any diagnosis of malignancy
made on specimens they receive. The site of tumour is coded to
a 4-digit diagnostic code based on the 7th revision of the
International Classification of Diseases (ICD-7) by the Swedish
Cancer Registry (see footnote to Table 1). We did not separate
acute and chronic leukaemia because acute lymphoid is less than
30% of all lymphoid leukaemia, and because chronic myeloid is
less that 20% of all myeloid leukaemia; furthermore, diagnostic
criteria for leukaemia have been modified over the years. Basal
cell carcinoma of the skin is not registered in the Cancer Registry.
The stage of the disease at diagnosis or treatment is not recorded. 
Patients 
All patients with an initial HLPD diagnosed between 1 January
1958 and 31 December 1996 were retrieved from the Database.
Cases of second primary malignancies were extracted if the diag-
nosis date of the first and second malignancy differed by at least 1
month. Between 1958 and 1996, a total of 3498 patients developed
a second primary malignancy among 53 159 HLPD patients. 
Statistical analysis 
Person-years at risk for second malignancy were accumulated for
each subject from the date of diagnosis of the first primary malig-
nancy to that of a second primary malignancy, date of death, date of
emigration, or December 31, 1996, whichever came first. Person-
years were classified by sex, 5-year age group, 5-year calendar
period (1958–1962, 1988–1992, 1993–1996), 2 types of residential
area (3 counties of large cities vs other), 4 occupational groups
(farmer, worker, professional and other), time since entry to the
cohort (< 1, 1–9 and > 9 years) and family history of HLPD in
parents and siblings. A cut-off point of 9 years after the first
diagnosis was selected to explore the potential radiotherapy- and
chemotherapy-induced risk for second primary malignancies
(Travis et al, 1991, 1993; Swerdlow et al, 1997, 2000; Metayer et al,
2000). 
Expected numbers were obtained by assuming that these
persons experienced the same cancer incidence as prevailed in the
corresponding general population in the Database and site-, sex-,
age-, period-, residence- and occupation-specific rates were
applied to the appropriate person-years at risk. Standardized inci-
dence ratios (SIR) of a second cancer were taken to be the ratio of
observed (O) to expected (E) numbers of second cancers.
Confidence intervals (95%CI) for SIR were calculated assuming
that the cases followed a Poisson distribution (Esteve et al, 1994). 
RESULTS 
Table 1 reports the characteristics of HLPD patients by subgroup.
Among 53 159 HLPD patients, with 264 190 person-years accu-
mulated, 36% (18 960/53 159) were NHL, 10% (5353/53 159)
HD, 16% (8656/53 159) myeloma, 15% (8098/53 159) lymphoid
leukaemia, 13% (1727/53 159) myeloid leukaemia and 9%
(4965/53 159) other leukaemia. Because other leukaemia is a
mixed group, it will not be considered in further analyses. A total
of 1.6% of HLPD (834/53 159) were familial. Familial lymphoma
and leukaemia showed an at least 12 years earlier median age of
onset than sporadic cases. Among 834 second primary malignan-
cies, 51 (6.1%) had an HLPD-affected parent or sib, including 8
for second HLPD, 4 for melanoma or squamous cell carcinoma of
the skin and 39 for solid tumours. Because of the small numbers,
familial cases were not analysed separately. 
Table 2 reports the overall risk of second primary cancer at
specific sites after NHL and HD. For NHL patients, there were
significant excesses of cancers of the tongue, small intestine, nose (2
of 6 cases were undifferentiated cancers), kidney, skin (squamous
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Table 1 Characteristics of patients with an initial HLPDa
Type of initial HLPD 
Characteristics NHL HD Myeloma Lymphoid Myeloid Other Total
leukaemia leukaemia leukaemia HLPD 
Number of patients 18 960 5353 8656 8098  7127 4965 53 159 
Male 11 137 3258 5036 5118 3909 2769 31 227 
Female 7823 2095 3620 2980 3218 2196 21 932 
Familialb 300 131 93 123 110 77 834 
Sporadic 18 660 5222 8563 7975 7017 4888 52 325 
Person-years at risk 94 088 46 206 32 255  43 330 21 776 26 535 264 190 
Median age at 1st diagnosis (years) 64 41 68  63 59 62 63 
Familial 52 29 65 51 40 48 50 
Sporadic 64 42 68 63 59 62 63 
Median length of follow-up (years) 2.5 5.5 2.5  3.5 1.5 2.5 2.5 
Number of second primary cancers 1354 411 475  659 170 429 3498 
Percent with second malignancy (%) 7.1% 7.7%  5.5% 8.1% 2.4% 8.6% 6.6% 
Median interval between 1st and 
2nd diagnosis (years)  4.4 9.3 2.9 3.8 1.9 6.2 6.5 
aNHL: Non-Hodgkin’s lymphoma (ICD-7 code: 200, 202); HD: Hodgkin’s lymphoma (ICD-7 code: 201); multiple myeloma (ICD-7 code: 203); lymphoid leukaemia
(ICD-7 code: 204); myeloid leukaemia (ICD-7 code: 205); other leukaemia (ICD-7 code: 206–209); HLPD: haematolymphopropoliferative disorder (ICD-7 code:
200–209). bFamilial: patients had a HLPD-affected parent or sib. 
BJOC 01-1998 997-1005  1/10/01  11:51 am  Page 998cell carcinoma, SCC), nervous system, NHL, HD and leukaemia,
whereas there were significant decreased risks of cancers of the
breast, endometrium and prostate. The SIR of 3.54 for SCC of skin
was the highest among all solid cancers. For HD patients, signifi-
cant excesses were seen for cancers of the salivary glands (5 cases,
2 of these undifferentiated), nasopharynx (3 cases, 2 undifferenti-
ated), stomach (18 cases, all but one adenocarcinomas), colon,
lung, breast, skin (both melanoma and SCC), nervous system,
thyroid, soft tissues and leukaemias. Compared with the general
population, NHL and HD patients had an excess of HLPD and skin
tumours, but only HD patients were at increased risk for all second
solid tumours (SIR = 1.40, 95% CI = 1.24–1.57). 
Table 3 presents the risks of second malignancies following
NHL by sex, age at first diagnosis and follow-up time at selected
sites where there was a significant excess. Males and females had
a similar risk pattern (increased or decreased) at all selected sites.
Increased risks of second malignancy were observed over all age
groups and follow-up times for small intestine, nose, skin SCC,
NHL, HD and leukaemias. The SIRs for cancers of the tongue,
small intestine and skin and for NHL, HD and LL were highest
when the age at first diagnosis was under 40 years. An increased
risk of breast cancer after NHL was confined to those whose age
at first diagnosis was under 40 years, whereas those whose age at
first diagnosis was ≥ 40 years had a significantly decreased risk
Second malignancy 999
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Table 2 Site-specific risk of second primary malignancy following HLPDa
Second cancer site Non-Hodgkin’s lymphoma  Hodgkin’s disease 
(ICD-7 code) O SIR (95% CI) O SIR  (95% CI) 
Lip (140) 8 1.29 (0.55 – 2.56) 1 0.72 (0.00  – 4.11) 
Tongue (141) 9 3.03 (1.38 – 5.78) 1 1.38 (0.00 – 7.90) 
Salivary glands (142) 5 2.10  (0.66 – 4.94) 5 8.00 (2.52 – 18.8)
Mouth (143, 144) 5 1.04 (0.33 – 2.44) 1 0.93 (0.00  – 5.35) 
Mesopharynx (145) 2 1.06 (0.10 – 3.88) 0 0.00 (0.00  – 8.12) 
Nasopharynx (146) 3 2.79 (0.53 – 8.26) 3 9.15 (1.73 – 27.1)
Hypopharynx (147) 1 0.51 (0.00 – 2.94) 0 0.00 (0.00  – 9.22) 
Other pharynx (148) 0 0.00 (0.00 – 30.6) 1 31.57 (0.01  – 181) 
Oesophagus (150) 10 1.00  (0.48 – 1.85) 3 1.54 (0.29 – 4.55) 
Stomach (151) 57 1.12 (0.85 – 1.45) 18 1.69 (1.00 – 2.68)
Small intestine (152) 16 3.10 (1.77 – 5.05) 0 0.00 (0.86 – 3.52) 
Colon (153) 73 0.82 (0.64 – 1.03) 29  1.72 (1.15 – 2.47)
Rectum (154) 39 0.75 (0.53 – 1.02) 1 1.09 (0.54  – 1.95) 
Anus (1541) 5 2.38 (0.75 – 5.60) 1 2.30 (0.00  – 13.2) 
Liver (155, 156) 42 1.13 (0.82 – 1.53) 7 1.01 (0.40  – 2.10) 
Pancreas (157) 28 0.78 (0.52 – 1.13) 8 1.13 (0.48  – 2.23) 
Nose and nasal sinuses (160) 6 3.25 (1.17 – 7.12) 0 0.00 (0.00 – 9.20) 
Larynx (161) 7 0.99 (0.39 – 2.06) 1 0.61 (0.00  – 3.52) 
Lung (162, 163) 99 1.08 (0.88 – 1.32) 34 1.80 (1.24 – 2.51)
Breast (170) 73 0.71 (0.56 – 0.89)4 5 1.73  (1.26 – 2.31)
Cervix (171) 9 0.90 (0.41 –1.71) 3 0.73 (0.14  – 2.16) 
Endometrium (172) 12 0.51 (0.26 – 0.90) 3 0.59 (0.11 – 1.75) 
Other uteri (173, 174) 3 1.26 (0.24 – 3.74) 0 0.00 (0.00 – 6.05) 
Ovary (175) 13 0.64 (0.34 – 1.09) 7 1.31 (0.52  – 2.72) 
Other female genital organs (176) 3 0.71  (0.13 – 2.10) 2 2.50 (0.24 – 9.19) 
Prostate (177) 159 0.75 (0.64 – 0.88) 33 0.94 (0.64 – 1.32) 
Testis (178) 5 2.58 (0.82 – 6.08) 0 0.00 (0.00  – 2.20) 
Other male genital organs (179) 3 1.39  (0.26 – 4.12) 0 0.00 (0.00 – 7.69) 
Kidney (180) 57 1.58 (1.20 – 2.05) 13 1.63 (0.86 – 2.79) 
Urinary bladder (181) 70 1.09 (0.85 – 1.37) 10 0.80 (0.38 – 1.49) 
Melanoma of the skin (190) 33 1.14 (0.78 – 1.60) 16 1.83 (1.04 – 2.98)
SCC of the skin (191) 167 3.54 (3.02 – 4.12)2 3 2.89  (1.83 – 4.35)
Eye (192) 1 0.38 (0.00 – 2.15) 2 2.90 (0.27  – 10.7) 
Nervous system (193) 40 1.45 (1.04 – 1.98)1 5 1.81  (1.01 – 3.00)
Thyroid (194) 7 1.07 (0.43 – 2.22) 10 4.60 (2.19 – 8.49)
Other endocrine glands (195) 23 1.32  (0.83 – 1.98) 3 0.66 (0.13 – 1.96) 
Bone (196) 1 0.77 (0.00 – 4.39) 1 1.92 (0.00  – 11.0) 
Soft tissues (197) 7 1.03 (0.41 – 2.14) 7 3.98 (1.58 – 8.26) 
Non-Hodgkin’s lymphoma (200, 202) 79 2.29 (1.82 – 2.86)4 1 5.53  (3.96 – 7.50)
Hodgkin’s disease (201) 25 6.53 (4.22 – 9.66) 3 1.81 (0.34 – 5.36) 
Myeloma (203) 16 0.88 (0.50 – 1.44) 4 1.13 (0.29  – 2.93) 
Lymphoid leukaemia (204) 53 4.07 (3.05 – 5.33)7 2.63  (1.04 – 5.44)
Myeloid leukaemia (205) 25 2.55 (1.65 – 3.77)1 9 7.67  (4.61 – 12.0)
Other leukaemia (206–209) 9 1.23 (0.56  – 2.35) 9 5.67 (2.57 – 10.8)
Other sites 46 1.14 (0.83 – 1.52 11 1.43 (0.71  – 2.56) 
All HLPD 207 2.39 (2.08 – 2.74)8 3 4.29 (3.42 – 5.32)
All skin sites 200 2.63 (2.28 – 3.02)3 9 2.34 (1.66 – 3.20)
All solid tissues 947 0.96 (0.90 – 1.02) 289 1.40 (1.24 – 1.57)
All sites 1354 1.18 (1.12 – 1.24)4 1 1 1.69 (1.53 – 1.86)
aSCC: squamous cell carcinoma; HLPD: haematolymphoproliferative disorder; O: observed cases; SIR: standardised incidence ratio; CI:
confidence interval; Bold type: 95% CI did not include 1.00. 
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BJOC 01-1998 997-1005  1/10/01  11:51 am  Page 1001(data not shown). A significant increase in cancer of the kidney
was confined to the first year of follow-up and this may be due to
increased surveillance or chance. An excess of bladder cancer
was confined to the period > 9 years of follow-up (data not
shown). 
Table 4 reports the risks of second malignancies following HD
by sex, age at first diagnosis and follow-up time at selected sites
where there was a significant excess. Males and females showed a
similar risk pattern (increased or decreased) for cancers of salivary
glands, lung, skin SCC, nervous system, thyroid and soft tissue
and for haematolymphoproliferative tissues except multiple
myeloma; by contrast, an increased risk of cancer of the
nasopharynx, stomach, colon and melanoma skin was confined to
male HD patients. An excess of female breast cancer was confined
to patients whose initial diagnosis age was under 40 years and the
period > 9 years of follow-up. Increased risks of cancers of colon,
skin and nervous system, NHL and leukaemia were observed over
all age groups and follow-up periods over 1 year. Increased risks
of cancers of salivary glands, nasopharynx, stomach, lung, thyroid
and soft tissues were mainly found in patients whose age at first
diagnosis was under 55 years and ≤ 1 year since HD diagnosis. An
increased risk of melanoma was seen in those under 65 years at
first diagnosis and follow up period ≤ 9 years, with the trend
decreasing from initial diagnosis. 
Table 5 reports risks following myeloma and leukaemia by
subgroup and follow-up time for second malignancies of skin,
nervous system, haematolymphoproliferative tissues and all solid
tissues. After myeloma, a significant increase was seen for SCC of
the skin in males but not in both sexes; for NHL the overall SIR
was increased. After lymphoid leukaemia, a significant increase in
SIR was seen for SCC of the skin and NHL during period ≥ 1 year
of follow-up and overall, for cancer of the nervous system during
period <1 and > 9 years of follow-up and overall, for HD,
lymphoid and myeloid leukaemia during 1–9 years of follow-up
and overall. After myeloid leukaemia, a significantly increased
risk was found only for recurrence. No excess of melanoma was
observed (data not shown). The SIR for melanoma was highest
after lymphoid leukaemia, 1.53 (n = 17, 95% CI, 0.89–2.43); 15 of
the cases were men, SIR 2.02 (95%CI, 1.13–3.34). 
DISCUSSION 
The Swedish Family-Cancer Database was used in the present
study and 6.1% of second HLPD cases had a family history of
HLPD, which was higher than that for first HLPD (1.6%). The
patients with a family history presented with their first HLPD on
average 12 years earlier than patients with a sporadic disease.
Our results are based on one of the largest cohorts of patients
1002 C Dong and K Hemminki
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Table 5 Site-specific risk of second malignancy following multiple myeloma and leukaemia by follow-up time and sexa
Year(s) after first diagnosis 
First cancer Second cancer site <1 1–9 >9 Total 
O SIR O SIR O SIR O SIR (95% Cl) 
Myeloma SCC of the skin 6 2.15 20 1.29 3 0.97 29 1.36 (0.91–1.95) 
Nervous system 4 2.68 11 1.36 0 0.00 15 1.39 (0.77–2.30) 
Non-Hodgkin’s lymphoma 4 2.08 19 1.78 2 1.11 25 1.74 (1.12–2.57) 
Hodgkin’s disease 0 0.00 2 1.70 0 0.00 2 1.25 (0.12–4.59) 
Myeloma 0 0.00 3 0.48 2 1.89 5 0.59 (0.19–1.38) 
Lymphoid leukaemia 0 0.00 2 0.46 1 1.33 3 0.51 (0.10–1.51) 
Myeloid leukaemia 1 1.72 30 9.50 4 7.43 35 8.19 (5.70–11.4) 
All HLPD 5 0.96 67 2.40 11 2.31 83 2.19 (1.74–2.71) 
All skin sites 6 1.42 29 1.23 4 0.92 39 1.22 (0.86–1.66) 
All solid tissues 64 1.08 248 0.77 41 0.73 353 0.81 (0.73–0.90) 
All sites 75 1.09 344 0.92 56 0.86 475 0.94 (0.86–1.03) 
Lymphoid SCC of the skin 2 0.96 98 6.14 21 4.33 121 5.28 (4.38–6.31) 
leukaemia Nervous system 7 6.09 91 . 0 8 63.10 22 1.93 (1.21–2.92) 
Non-Hodgkin’s lymphoma 0 0.00 47 4.33 11 3.94 58 3.85 (2.92–4.98) 
Hodgkin’s disease 0 0.00 6 4.60 25 . 3 9 8 4.29 (1.83–8.50) 
Myeloma 0 0.00 2 0.32 1 0.64 3 0.35 (0.07–1.04) 
Lymphoid leukaemia 1 1.34 13 2.67 32 . 5 5 1 7 2.51 (1.46–4.02) 
Myeloid leukaemia 1 2.27 10 3.13 00 . 0 0 1 1 2.46 (1.22–4.42) 
All HLPD 2 0.51 81 2.80 18 2.44 101 2.51 (2.05–3.05) 
All skin sites 4 1.28 112 4.67 22 3.18 138 4.06 (3.41–4.79) 
All solid tissues 58 1.33 299 0.92 63 0.75 420 0.93 (0.84–1.02) 
All sites 64 1.26 492 1.30 103 1.04 659 1.25 (1.16–1.35) 
Myeloid SCC of the skin 1 0.68 12 3.44 0 0.00 13 1.66 (0.88–2.85) 
leukaemia Nervous system 1 1.04 8 2.62 1 0.73 10 1.86 (0.88–3.43) 
Non-Hodgkin’s lymphoma 0 0.00 4 1.34 0 0.00 4 0.69 (0.18–1.79) 
Hodgkin’s disease 0 0.00 0 0.00 0 0.00 0 0.00 (0.00–4.51) 
Myeloma 0 0.00 3 1.89 0 0.00 3 0.93 (0.18–2.77) 
Lymphoid leukaemia 0 0.00 4 3.41 1 1.38 5 2.13 (0.67–5.01) 
Myeloid leukaemia 2 4.86 13 12.8 23 . 8 0 1 7 8.70 (5.06–14.0) 
All HLPD 2 0.68 30 3.78 30 . 6 5 3 5 2.25 (1.57–3.14) 
All skin sites 1 0.42 14 2.18 0 0.00 15 1.15 (0.64–1.90) 
All solid tissues 29 0.87 76 0.84 15 0.28 120 0.68 (0.56–0.81) 
All sites 32 0.83 120 1.15 18 0.29 170 0.83 (0.71–0.96) 
aSCC: squamous cell carcinoma; HLPD: haematolymphoproliferative disorder; O: observed cases; SIR: standardised incidence ratio; CI: confidence
interval: Bold type: 95% CI did not include 1.00. 
BJOC 01-1998 997-1005  1/10/01  11:51 am  Page 1002with HLPD studied to date (totalling 53 159 patients, 264 190
person-years), enabling us to analyse site-specific risk of second
cancer following HLPD. The large dataset permits description of
age and latency patterns for second cancer risk at a broad spec-
trum of anatomic sites. In addition, the estimation of SIRs was
based on adjustment for period, residence and socio-economic
status, which may be potential confounding factors and mainly
unadjusted in previous studies. Period is important, particularly
for NHL, which has increased in incidence throughout the
follow-up period, and even for other HLPDs because of changes
in treatment. Although our data lack information about treat-
ment, we divided the follow-up time into 3 periods, <1, 1–9 and
> 9 years. The period > 9 years of follow-up may reveal the
effects due to radiotherapy and chemotherapy at most solid
tumours but leukaemias appear earlier (Travis et al, 1991, 1993;
Swerdlow et al, 1997, 2000; Metayer et al, 2000); the first year of
diagnosis may include recurrences and reveal the effects of
medical surveillance. We consider the effect of follow-up in
subsequent discussion. 
HLPDs are a number of heterogeneous but related conditions.
However, misclassification, particularly NHL to HD, may have
taken place in the past (Travis et al, 1991; Abrahamsen et al, 1997;
Kumar et al, 1997). The distinction between the related conditions,
NHL and chronic LL, may also have been unclear in the past
(Adami et al, 1995). The classification of HLPDs has undergone
many changes during the past decades and whether these changes
have affected the broad categories used in the present study
remains unknown. 
Treatment of HLPDs has undergone major changes during the
period of the present study, 1958–96. Chemotherapy and radio-
therapy have been used throughout the period but new antineo-
plastic agents and more aggressive therapies have been introduced
(Adami et al, 1995). For some HLPDs, prognosis has improved
markedly and, for example, the 5-year survival from HD has
improved 3-fold in Sweden between 1962 and 1988 (Stenbeck and
Rosen, 1995). The respective improvements for NHL, multiple
myeloma and leukaemias have been about 1.5-fold. Radiotherapy
and many types of chemotherapy carry a risk for second cancers
and treatment of HD is known to increase the risks of acute
leukaemia, NHL and of lung, gastro-intestinal, breast, thyroid,
bone and connective tissue cancer (Kumar et al, 1997; Metayer 
et al, 2000; Swerdlow et al, 2000). 
NHL, HD, leukaemia and myeloma 
Many studies have been published on second cancers after NHL.
Common findings have been increases in acute leukaemia, cancers
at lung, bladder, soft tissues, thyroid and kidney, melanoma and
HD (Travis et al, 1991, 1993; Brennan et al, 2000). Excesses in
melanoma and, particularly, skin SCC have been observed after
NHL and chronic lymphoid leukemia (Adami et al, 1995; Levi
et al, 1996). The present study, only second to the Adami study in
accumulated person-years, noted increases in tongue, small
intestinal, nasal, bladder, skin (SCC but not melanoma), and
nervous system cancers, in addition to all types of HLPD. Many of
these increases in earlier studies, have been ascribed to the effects
of treatment, though other possible causes have probably been
overlooked (Travis et al, 1991). In contrast, we found no increases
in gastro-intestinal (except for small intestine) and lung cancers
nor, notably, in melanoma. On the other hand, details of nasal
cancer (our SIR 3.25) have been reported in only one study and no
increase was noted (Brennan et al, 2000). We have recently drawn
attention to the occurrence of nasal cancer as a second cancer after
skin SCC and speculated on the possible aetiological role of EBV,
perhaps in immunocompromised individuals (Hemminki and
Dong, 2000b, 2000c). We have recently noted an excess of second
NHL after nasal cancer (Dong and Hemminki, 2001b). These
epidemiological findings may not be fortuitous. Another site,
which was increased after NHL, was the nervous system; this site
was also in excess after lymphoid leukaemia and the association is
thus unlikely to be fortuitous. An increase has also been noted in a
previous study (SIR 2.33) and in another one for males only
(Travis et al, 1991, 1993). Treatment effects in nasal and nervous
system tumours were not suggested when the risks were analysed
according to the follow-up time (Table 3). 
NHL and HD were increased after each other, with high SIRs of
5.5–6.5 (Table 2). Both have been treated with aggressive therapy.
Yet the spectrum of second malignancies observed was quite
different: among solid tumours only skin SCC and nervous system
cancers were increased after both NHL and HD. One reason for the
different effects may be in the age distribution; the median age of
the first HD diagnosis was 41 years compared to 64 for NHL.
There may also be other biological explanations. Many large
follow-up studies have been carried out after HD with the aim of
quantifying carcinogenic risks of radiation and chemotherapy
(Swerdlow et al, 1997, 2000; Metayer et al, 2000). All the sites
that were increased in the present study were also noted in these
previous studies, including salivary glands and upper aerodiges-
tive tract (without further subdivision), but with the notable excep-
tion of skin cancer. The SIR for nonmelanoma skin cancer was 1.4
in the English study and it was excluded from further analysis
because registration was assumed to be seriously incomplete
(Swerdlow et al, 2000). Skin cancer and melanoma are discussed
below. 
It is of interest that nasopharynx (SIR 9.15) and stomach (SIR
1.69) together with HD and certain types of NHL are considered as
potentially EBV-related (IARC, 1997). The increases at salivary
glands and nasopharynx were the highest among second malignan-
cies after HD. Histology showed that more than expected of these
tumours were undifferentiated cancers though the number of cases
was small. Analysis by follow-up time (Table 4) showed increases
in SIR towards the end of follow-up, suggesting either treatment
related effects or possibly slow malignant viral transformation. 
Myeloma was followed by an excess of NHL and leukaemia.
Lymphoid leukaemia was followed by excesses of skin SCC (SIR
5.28), nervous system cancer (1.93), and many types of HLPD. The
distribution of skin and nervous system cancers after diagnosis of
lymphoid leukaemia gave no suggestion of being treatment-related. 
Melanoma and SCC of skin following HLPD 
UVR is a common risk factor for melanoma and skin SCC. For
skin SCC, the total life-time UVR-dose is considered important;
for melanoma high intermittent exposures in childhood and
adolescence are considered important (Adami et al, 1995; English
et al, 1997). A second aetiological factor is defective immune
function and skin SCC and NHL are greatly increased in organ
transplant patients (Kinlen, 1992; IARC, 1997). The third aetio-
logical factor could be chemo- and radiotherapy, radiation being
known to increase the risk of skin SCC though data on
chemotherapy are not consistent (IARC, 1990; Metayer et al,
2000; Swerdlow et al, 2000). 
Second malignancy 1003
British Journal of Cancer (2001) 85(7), 997–1005 © 2001 Cancer Research Campaign
BJOC 01-1998 997-1005  1/10/01  11:51 am  Page 10031004 C Dong and K Hemminki
British Journal of Cancer (2001) 85(7), 997–1005 © 2001 Cancer Research Campaign
An excess of melanoma after NHL and chronic lymphoid
leukaemia has been observed in most previous studies (Travis
et al, 1991, 1993; Adami et al, 1995; Levi et al, 1996; Brennan et
al, 2000), whereas our data were negative for NHL and only
marginally positive for lymphoid leukaemia. After HD, melanoma
was increased but the highest SIR was found immediately after the
initial diagnosis, suggesting surveillance bias. In most of the
previous studies, cited above, the risks for melanoma were also
high immediately after the initial diagnosis. Taken together, the
data suggest a modest increase of melanoma risk after NHL and
chronic lymphoid leukaemia. 
The case for skin SCC is much stronger. In an earlier study the
risks after both NHL and chronic lymphoid leukaemia were more
than 2 times higher for skin SCC than melanoma (Adami et al,
1995). Excesses of NHL and chronic lymphoid leukaemia have
been noted after skin SCC (Adami et al, 1995; Levi et al, 1996).
An increase in all lymphomas, 80% of which were NHL, has been
observed even after in situ SCC of skin, a benign tumour for which
the primary treatment has been surgery only (Hemminki and
Dong, 2000c). The present data were convincing showing high
SIRs for skin SCC after NHL, HD and lymphoid leukaemia. The
excess of skin SCC after HD, only previously documented for
non-melanoma skin cancer (Swerdlow et al, 1997) was robust 
(n = 23, SIR 2.89, 95%CI, 1.83–4.35). There was no evidence that
the excess of skin SCC as a second malignancy was due to surveil-
lance bias or therapy. 
Conclusions 
There has been much interest in the aetiology of NHL, melanoma
and skin SCC because they have increased in most Western coun-
tries, in Sweden more than any other cancer (Centre for
Epidemiology, 1999). Our data unify the fragmentary earlier
evidence to point to the aetiological links between NHL, HD,
chronic lymphoid leukaemia and skin SCC. The common mecha-
nism may be a (possibly) transient impairment of immunological
surveillance that allows escape of tumours cells and formation of
SCC. Depressed immune function may also be a contributing
cause for the initial NHL, HD and lymphoid leukaemia, and the
long-term chemo- and radiotherapy may increase such depression.
This interpretation will not explain the worldwide temporal
increase in NHL alone among HLPDs (Cartwright et al, 1994).
However, data on the temporal trends on subtypes of leukaemias
are limited and those on HD show complex patterns of increase
among young and large decrease among old patients (Abrahamsen
et al, 1997; Chen et al, 1997). UVR-induced immunosuppression
has been suggested to contribute to the increasing trends in both
NHL and melanoma, or, as consistent with our results, in NHL and
skin BCC (Cartwright et al, 1994; Adami et al, 1995; Levi et al,
1996; Brennan et al, 2000). There is evidence from epidemiolog-
ical studies on melanoma that use of sunscreens is a risk factor for
melanoma (IARC, 2001). Among the 15 case–control studies on
melanoma reviewed by the IARC working group, 8 showed signif-
icantly higher risks among sunscreen users. Although some of
these studies may have problems with confounding, the increasing
use of sunscreens deserves further research. Allergies, asthma and
atopy are other immune-related groups of diseases that have been
increasing in prevalence in the developed world. In these condi-
tions the immune system is hyperactive, and there is evidence for
allergies protecting against NHL (Volkers, 1999). 
We observed associations to putative EBV-related sites, salivary
glands, nasopharynx and stomach after HD; nasal cancer was
increased after NHL but the link to EBV remains to be established.
Undifferentiated cancers were in excess at sites other than the
stomach and the number of cases was too small to allow conclu-
sions. Nervous system cancer was the only solid tumour, together
with skin SCC, that was increased after NHL, HD and lymphoid
leukaemia. 
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